Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A phase 1 trial of sotorasib in 129 patients – including Australians – with mainly non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) has found no dose-limiting toxic effects or treatment-related deaths associated with ...
Drugging the undruggable? KRAS inhibitor shows early promise
By Mardi Chapman
24 Sep 2020